Related Experiment Videos
Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia
Bernard M Fine1, Martin Stanulla, Martin Schrappe
1Division of Hematology, 269 Campus Dr, CCSR 1155, Stanford University School of Medicine, Stanford, CA 94305-5156, USA. lboxer@stanford.edu
Blood
|October 4, 2003
Summary
Chromosomal abnormalities in acute lymphoblastic leukemia (ALL) create distinct gene expression signatures. TEL/AML1 ALL shows high erythropoietin receptor (EPOR) expression, unlike BCR/ABL or MLL ALL.
Area of Science:
- Genomics
- Molecular Biology
- Oncology
Background:
- Pediatric acute lymphoblastic leukemia (ALL) is often characterized by specific chromosomal abnormalities.
- Understanding gene expression patterns associated with these abnormalities is crucial for diagnosis and treatment.
Purpose of the Study:
- To globally analyze gene expression in ALL cell lines and patient samples harboring specific chromosomal abnormalities.
- To identify characteristic gene expression signatures linked to TEL/AML1, BCR/ABL, and MLL abnormalities.
- To discover novel genes associated with these ALL subtypes.
Main Methods:
- Gene expression profiling of ALL cell lines and pediatric ALL samples.
- Comparative analysis of transcriptional programs across different chromosomal abnormality subtypes.
- Systematic identification of genes associated with TEL/AML1, BCR/ABL, and MLL abnormalities.
Main Results:
- Chromosomal abnormalities were the primary drivers of transcriptional variation in ALL cell lines.
- Distinct, shared gene expression signatures were identified for TEL/AML1, BCR/ABL, and MLL abnormalities in both cell lines and clinical samples.
- BCR/ABL ALL exhibited a more heterogeneous expression pattern compared to TEL/AML1 and MLL ALL.
- The erythropoietin receptor (EPOR) was found to be consistently overexpressed in TEL/AML1 ALL.
Conclusions:
- Specific chromosomal abnormalities in pediatric ALL are associated with characteristic and shared gene expression signatures.
- BCR/ABL ALL presents a more complex molecular landscape than TEL/AML1 or MLL ALL.
- Identification of novel genes, including EPOR, associated with these ALL subtypes offers potential new avenues for research and therapeutic strategies.